Astilbin protects from sepsis‐induced cardiac injury through the NRF2 / HO ‐1 and TLR4 / NF‐κB pathway
Phytotherapy Research · 2024
DOI: 10.1002/ptr.8093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, 2024. Verfasst von Zhao Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Heart Diseases, Cardiomyopathies, Sepsis, Flavonols. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Nature Science Foundation of China, Wuhan Knowledge Innovation Special Dawn Plan Project.
Themen: Sepsis
Abstract (Originalsprache)
Cardiac dysfunction and arrhythmia are severe complications of sepsis‐induced cardiomyopathy and are associated with an increased risk of morbidity and mortality. Currently, the precise mechanism for sepsis‐induced myocardial damage remains unclear. Astilbin, a flavonoid, is reported to have anti‐inflammatory, antioxidative, and antiapoptotic properties. However, the effects of astilbin on sepsis‐induced cardiomyopathy have not been studied so far. This study aims to investigate the effect of astilbin in sepsis‐induced myocardial injury and elucidate the underlying mechanism. In vivo and in vitro sepsis models were created using lipopolysaccharide (LPS) as an inducer in H9C2 cardiomyocytes and C57BL/6 mice, respectively. Our results demonstrated that astilbin reduced myocardial injury and improved cardiac function. Moreover, astilbin prolonged the QT and corrected QT intervals, attenuated myocardial electrical remodeling, and promoted gap junction protein (Cx43) and ion channels expression, thereby reducing the susceptibility of ventricular fibrillation. In addition, astilbin alleviated LPS‐induced inflammation, oxidative stress, and apoptosis. Astilbin suppressed the toll‐like receptor 4 (TLR4)/nuclear factor‐κB (NF‐κB) pathway in vivo and in vitro models. Astilbin remarkedly upregulated the nuclear factor erythroid 2‐related factor 2 (NRF2) and heme oxygenase 1 (HO‐1) expression. The in vitro treatment with an NRF2 inhibitor reversed the inhibition of the TLR4/NF‐κB pathway and antioxidant properties of astilbin. Astilbin attenuated LPS‐induced myocardial injury, cardiac dysfunction, susceptibility to VF, inflammation, oxidative stress, and apoptosis by activating the NRF2/HO‐1 pathway and inhibiting TLR4/ NF‐κB pathway. These results suggest that astilbin could be an effective and promising therapeutics target for the treatment of sepsis‐induced cardiomyopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
- Cardiovascular Research Institute, Wuhan University, Wuhan, China.
- Hubei Key Laboratory of Cardiology, Wuhan, China.
- Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Cardiovascular Disease Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.
- Hubei Selenium and Human Health Institute, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.
ORCID-Profile: Chengyin Liu
Förderung
- Nature Science Foundation of China
- Wuhan Knowledge Innovation Special Dawn Plan Project
Zitieren
APA
Fang, Z., Wang, G., Huang, R., Liu, C., Yushanjiang, F., Mao, T., & Li, J. (2024). Astilbin protects from sepsis‐induced cardiac injury through the NRF2 / HO ‐1 and TLR4 / NF‐κB pathway. Phytotherapy Research. https://doi.org/10.1002/ptr.8093
Vancouver
Fang Z, Wang G, Huang R, Liu C, Yushanjiang F, Mao T, et al. Astilbin protects from sepsis‐induced cardiac injury through the NRF2 / HO ‐1 and TLR4 / NF‐κB pathway. Phytotherapy Research. 2024. doi:10.1002/ptr.8093
BibTeX
@article{Fang2024,
author = {Fang, Zhao and Wang, Guangji and Huang, Rui and Liu, Chengyin and Yushanjiang, Feierkaiti and Mao, Tuohua and Li, Jun},
title = {Astilbin protects from sepsis‐induced cardiac injury through the NRF2 / HO ‐1 and TLR4 / NF‐κB pathway},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.8093}
}
EUVIMED